IP Library Granted Patent US 7,341,839
Granted Patent B2
US 7,341,839 · App. 11/523,954 · Granted Mar 11, 2008

Diagnostic methods for age related macular degeneration

Assignees: The Cleveland Clinic Foundation; Case Western Reserve University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,341,839
App. No.
11/523,954
Granted
Mar 11, 2008
Kind
B2
Abstract

Diagnostic methods for identifying a test subject who has or is at risk of developing age-related macular degeneration (AMD) or an analogous disease associated with oxidation of DHA-containing lipids are provided. In one aspect, the methods comprise: assaying for the presence of elevated levels of 2-(ω-carboxyethyl) pyrrole (CEP) adducts in a bodily fluid which has been obtained from the test subject. In a preferred embodiment, such methods comprise providing an antibody that is immunospecific for CEP, contacting a bodily fluid from the subject with the anti-CEP antibody, and assaying for the formation of a complex between the antibody and an antigen in the sample. In another aspect, the methods comprise assaying for the presence of elevated levels of an antibody that binds to or is immunospecific for a CEP adduct in the bodily fluid of the test subject. The present invention also relates to CEP protein and peptide adducts, an antibody reactive with a CEP adduct and a diagnostic kit comprising such antibody.

Claims (4)

1. A method of diagnosing age-related macular degeneration (AMD) in a test subject, comprising

determining the level of anti-2-(ω-carboxyethyl) pyrrole (CEP) antibodies in a bodily fluid obtained from the test subject, wherein the presence of an elevated level of anti-CEP antibodies in the test subject's bodily fluid as compared to a control value based on the level of anti-CEP antibodies found in a corresponding bodily fluid obtained from control subjects indicates that the test subject is more likely to have AMD than a test subject whose levels of anti-CEP antibodies are equal to or less than the control value.

2. The method of claim 1 , wherein the bodily fluid is whole blood, serum, or plasma.

3. The method of claim 1 , wherein levels of anti-CEP antibodies in the bodily fluid are determined by contacting the bodily fluid with a CEP adduct and assaying for the formation of an antigen-antibody complex between the CEP adduct and antibodies in the bodily fluid.

Assignments (1)
CONFIRMATORY LICENSE Recorded Nov 15, 2017
From: CASE WESTERN RESERVE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 044455/0403 →
Continuity (3)
Division 1013519600 · Apr 30, 2002
Provisional Application 6028754300 · Apr 30, 2001
Related Publication 20070072241A1 · Mar 29, 2007